D0834 | cannabinol
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 1.68±0.00 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 1.09 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 21.82±0.00 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Warning |
Aggregated GHS information provided by 3 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. Reported as not meeting GHS hazard criteria by 1 of 3 companies. For more detailed information, please visit ECHA C&L website Of the 2 notification(s) provided by 2 of 3 companies with hazard statement code(s): H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral] H315 (50%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (50%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H335 (50%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure Respiratory tract irritation] H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo(b,d)pyran | 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran | 3-Amyl-1-hydroxy-6,9-trimethyl-6H-dibenzo[b,d]pyran |
| 5-17-04-00567 (Beilstein Handbook Reference) | 521-35-7 | 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol |
| 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol # | 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol (Cannabinol) | 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol(Cannabinol) |
| 6,6,9-Trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol | 6,6,9-Trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol. Product derived from Cannabis sativa | 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol |
| 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol | 6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol | 6H-Dibenzo(b,d)pyran-1-ol, 6,6,9-trimethyl-3-pentyl- |
| 6H-Dibenzo[b, 6,6,9-trimethyl-3-pentyl- | 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl- | 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl- (7CI,8CI,9CI) |
| 7UYP6MC9GH | AKOS024457448 | BDBM50061117 |
| BRN 0237145 | C07580 | CAS-521-35-7 |
| CHEBI:3360 | CHEMBL74415 | Cannabinol (6CI) |
| Cannabinol (CBN) 100 microg/mL in Methanol | Cannabinol (CBN) 1000 microg/mL in Methanol | Cannabinol 1.0 mg/ml in Methanol |
| Cannabinol [INN:BAN] | Cannabinol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material | Cannabinol solution, 1.0 mg/mL in methanol, analytical standard, for drug analysis; |
| Cannabinol, analytical standard | Cannabinolo | Cannabinolo [DCIT] |
| Cannabinolum | Cannabinolum [INN-Latin] | DB14737 |
| DSSTox_CID_28922 | DSSTox_GSID_48996 | DSSTox_RID_83188 |
| DTXSID3048996 | DivK1c_000972 | FT-0664223 |
| GTPL740 | HMS503C05 | IDI1_000972 |
| KBio1_000972 | L000158 | LMPK13120002 |
| LS-61184 | NCGC00168261-01 | NINDS_000972 |
| NSC 134455 | NSC-134455 | NSC134455 |
| Q265831 | SCHEMBL121085 | Tox21_113486 |
| UNII-7UYP6MC9GH | VBGLYOIFKLUMQG-UHFFFAOYSA-N | WLN: T B666 HO IHJ CQ E5 I1 I1 M1 |
| ZINC1530833 | cannabinol |
| DrugBank Name | cannabinol |
| DrugBank | DB14737 |
| CAS Number | 521-35-7 |
| PubChem Compound | 2543 |
| KEGG Compound ID | C07580 |
| ChEBI | 3360 |